新型气道球囊冷冻消融系统治疗恶性中心气道梗阻的疗效与安全性:前瞻性多中心随机非劣效研究
该前瞻性多中心随机非劣效研究纳入198例恶性中心气道梗阻患者,1:1分配至新型气道球囊冷冻消融(ABC)系统组或ERBOKRYOCA冷冻手术(EC)系统组。干预6周后ABC组气道通畅率78.49%,EC组60.92%,差异17.58%(95%CI 4.35%至30.80%,p<0.001),超过-10%非劣效界值。两组mMRC和KPS评分均改善且无差异,ABC组冷冻消融时间显著缩短,出血发生率相似,无危及生命事件。
要点
- ABC系统在6周气道通畅率上非劣效且优于传统EC系统。
- ABC组冷冻消融时间显著短于EC组(378.29±399.54 s vs 624.93±443.72 s)。
- 两组mMRC和KPS评分改善无差异,出血发生率相似且无危及生命事件。
核心结论
- ABC系统在恶性中心气道梗阻患者中6周气道通畅率非劣效且随后优于传统二氧化碳驱动冷冻探针。
- 研究支持该新型系统作为支气管镜下冷冻消融的替代方案用于恶性中心气道梗阻患者。
研究设计与样本
- 前瞻性、随机、对照、非劣效研究,在中国15个中心纳入恶性中心气道梗阻患者。
- 患者按1:1比例分配至ABC组和ERBOKRYOCA冷冻手术(EC)系统组,共198例随机。
- 冷冻消融前允许采用多模态方法进行气道肿瘤减容。
- 主要结局为干预6周后气道通畅率,非劣效界值为-10%。
主要发现
- 干预6周后ABC组气道通畅率为78.49%,EC组为60.92%。
- 两组差异为17.58%(95%CI 4.35%至30.80%),p<0.001,超过-10%非劣效界值。
- 两组mMRC和KPS评分在3周和6周后均显著改善,组间无差异。
- ABC组冷冻消融时间显著缩短(378.29±399.54 s vs 624.93±443.72 s,p<0.001)。
- 两组出血发生率相似,无危及生命事件。
关键数值与推荐
- 主要结局非劣效界值为-10%。
- ABC组6周气道通畅率78.49%,EC组60.92%,差异17.58%(95%CI 4.35%至30.80%),p<0.001。
- ABC组冷冻消融时间378.29±399.54 s,EC组624.93±443.72 s,p<0.001。
临床怎么用
- 对于恶性中心气道梗阻患者,可考虑使用ABC系统进行支气管镜下冷冻消融以维持气道通畅。
- ABC系统冷冻消融时间更短,可能有助于提高操作效率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A novel airway balloon cryoablation (ABC) system using liquid nitrogen as cryogen was developed for bronchoscopic intervention in malignant central airway obstruction (MCAO). This study aimed to evaluate the efficacy and safety of this system. METHODS: This was a prospective, randomised, controlled, non-inferiority study that enrolled MCAO patients at 15 sites in China. Patients were assigned to the ABC group and the ERBOKRYOCA Cryosurgical (EC) system group in a 1:1 ratio. Airway tumour debulking with multimodality was permitted before cryoablation. The primary outcome was the airway patency rate after 6 weeks of intervention with a non-inferiority margin of -10%. Secondary outcomes included modified Medical Research Council (mMRC) Dyspnoea Scale and Karnofsky Performance Scale (KPS) assessment, and the duration of cryoablation. RESULTS: 198 patients were randomised. After 6 weeks of intervention, the airway patency rate was 78.49% in the ABC group and 60.92% in the EC group, showing that the difference was over the non-inferiority margin of -10% at 17.58% (95% CI 4.35% to 30.80%), p<0.001. The mMRC and KPS scores were significantly improved after 3 and 6 weeks in both groups, with no difference. The duration of cryoablation was shortened remarkably in the ABC group (378.29±399.54 s vs 624.93±443.72 s, p<0.001). The prevalence of bleeding was similar in the two groups, without life-threatening events. CONCLUSIONS: The ABC system provided non-inferior and subsequent superior effect in airway patency rate compared with traditional carbon dioxide-driven cryoprobe in MCAO. This study supports this novel system as an alternative to cryoablation via bronchoscope for MCAO patients. TRIAL REGISTRATION NUMBER: ChiCTR2100042051.
引用
- Liu J, Li C, Gu Y, et al. Efficacy and safety of novel airway balloon cryoablation system for malignant central airway obstruction: a prospective, multicentre, randomised, non-inferiority study. Thorax. 2025. PMID: 40796274. doi:10.1136/thorax-2024-222745
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。